Abstract 75P
Background
As part of key subgroup analyses of EMPOWER-lung 3 (NCT03409614), a double-blinded, randomized (2:1) phase 3 trial, an improvement in overall survival (OS) was observed with cemiplimab + chemotherapy (CEMI+CHEMO, n=47) vs placebo + chemotherapy (CHEMO, n=23) in patients with baseline liver metastases from advanced NSCLC (median OS: 14.4 vs 8.9 months; hazard ratio (HR): 0.61 (95% confidence interval (CI): [0.31, 1.20]). The safety results of patients with baseline liver metastases were generally similar to those of the overall study population. We conducted exploratory analyses to evaluate PROs within this subgroup of patients.
Methods
PROs were assessed at day 1 (baseline), the start of each treatment cycle (every 3 weeks) for the first 6 doses, and then at start of every third cycle, using the EORTC-QLQ-C30 and -QLQ-LC13 questionnaires. A mixed-effect model for repeated measures analysis was performed to compare CEMI+CHEMO vs CHEMO for all scales. Time to definitive clinically meaningful deterioration (TTD) was evaluated using Kaplan-Meier analysis and between-arm TTD comparisons were made using a log-rank test and proportional hazards model.
Results
Statistically significant delay in TTD was observed favouring CEMI+CHEMO over CHEMO for role functioning (HR: 0.28, 95% CI [0.10, 0.79]; p=0.011), cognitive functioning (0.18, [0.06, 0.55]; p=0.001), haemoptysis (<0.01, [<0.01, not calculable]); p=0.021), and alopecia (0.25, [0.09, 0.72]; p=0.007). When comparing between arms, no statistically significant differences between CEMI+CHEMO vs CHEMO in overall change from baseline across all C30 or LC13 scales were observed. No analyses yielded statistically significant PRO results favouring CHEMO vs CEMI+CHEMO for any C30 or LC13 scales.
Conclusions
Among patients with baseline liver metastases from advanced NSCLC, CEMI+CHEMO resulted in significant delay in TTD in role functioning, cognitive functioning, haemoptysis, and alopecia when compared with CHEMO. Overall change from baseline across all PROs were maintained. These PRO results further support the favourable benefit–risk profile of CEMI+CHEMO vs CHEMO in advanced NSCLC with baseline liver metastases.
Clinical trial identification
NCT03409614.
Editorial acknowledgement
Editorial support was provided by John G Facciponte, PhD, of Prime, Knutsford, UK.
Legal entity responsible for the study
Regeneron Pharmaceuticals, Inc.
Funding
Regeneron Pharmaceuticals, Inc., and Sanofi.
Disclosure
A. Baramidze: Other, Personal, Other, Travel support: Regeneron Pharmaceuticals, Inc. C. Gessner: Financial Interests, Personal, Advisory Board: AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, GSK, Novartis, Merck Sharp & Dohme, Pfizer, Roche, Sanofi. A. Sezer: Financial Interests, Institutional, Funding: Roche, Merck Sharp & Dohme, Merck Serono, AstraZeneca, Lilly, Novartis, Johnson & Johnson, Regeneron Pharmaceuticals, Inc., Sanofi. M. Gumus: Financial Interests, Personal, Other, Honoraria: Roche, Merck Sharp & Dohme, Gen İlaç, Novartis. X. He, G. Gullo, P. Rietschel, R. Quek: Financial Interests, Personal, Full or part-time Employment: Regeneron Pharmaceuticals, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
1P - Integrated Data Analysis within IMMUcan Identifies Prognostic Features of Early NSCLC
Presenter: Daniel Schulz
Session: Poster Display
3P - Exploratory efficacy analysis by smoking status in PD-L1 high patients in the phase III, non-small cell lung cancer (NSCLC) IMpower110 study
Presenter: Luis Paz-Ares
Session: Poster Display
4P - Immune exoproteome, soluble proteome and immune-related gene expression profiles of anti-PD-1 therapy in stage IIIB/IV Non-Small Cell Lung Cancer: relevance of immunosuppressive factors
Presenter: Paulo Santos
Session: Poster Display
5P - Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC
Presenter: Giulia Mazzaschi
Session: Poster Display
6P - CD161+CD127+CD8+ T cells as a critical predictor of the efficacy of anti-PD-1 immunotherapy in diabetic patients with non-small cell lung cancer
Presenter: Jingjing Qu
Session: Poster Display
7P - A T-cell-derived circulating DNA as a biomarker for response to anti-PD(L)1 immunotherapy in advanced stage non-small cell lung cancer
Presenter: Nuthchaya Mejun
Session: Poster Display
9P - Primary NSCLC patient-derived microtumors (PMTs) for clinical-relvant prediction of immunotherapy efficacy
Presenter: Fabienne Nocera
Session: Poster Display
11P - Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer
Presenter: Liang Zheng
Session: Poster Display
12P - Spatially preserved multi-region transcriptomic subtyping and biomarkers associated with long-term benefit with chemoimmunotherapy in extensive-stage small cell lung cancer (ES-SCLC)
Presenter: Melina Peressini Álvarez
Session: Poster Display